-+ 0.00%
-+ 0.00%
-+ 0.00%

GT BIOPHARMA PROVIDES ENROLLMENT UPDATE ON GTB-3650 PHASE 1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD33 EXPRESSING HEMATOLOGIC MALIGNANCIES

Reuters·10/08/2025 13:00:02

Please log in to view news